Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants Emergency Use Authorization for DiaCarta Multiplex Coronavirus Test

NEW YORK — The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for DiaCarta's QuantiVirus SARS-CoV-2 Multiplex Test Kit.

The test is designed to detect the SARS-CoV-2 Orf1ab gene in upper respiratory specimens and sputum, according to Richmond, California-based DiaCarta. Nucleic acid purification is performed using either MGI Tech's MGIEasy Magnetic Beads Virus DBA/RNA Extraction Kit or Thermo Fisher Scientific's PureLink Viral RNA/DNA Mini Kit, and the test runs on Thermo Fisher's Applied Biosystems QuantStudio 5 RT-PCR instrument or Bio-Rad's CXF384 RT-PCR system.

The test may be used by any lab CLIA-certified to perform high-complexity tests.

In April, DiaCarta said it received EUA for its QuantiVirus SARS-CoV-2 Test Kit, which detects the virus' Orf1ab, N, and E genes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.